Cipla to launch anti-malarial drug in Africa, South-East Asian countries

摘要

Cipla is set to launch a fixed-dose combination of Arte-sunate (AS) and Mefloquine (MQ) for the treatment of falciparum malaria. The two-in-one combination targeting drug-resistant falciparum malaria has been developed by Cipla in collaboration with the Drugs for Neglected Diseases Initiative (DNDi), a not-for-profit R&D organisation working to deliver new treatments for neglected diseases.The combination therapy simplifies a patient's treatment to a single doseof one or two tablets for three days - ensuring patient adheres to the treatment regime and the medicines are taken in correct proportions.